IP Library Granted Patent US 7,582,645
Granted Patent B2
US 7,582,645 · App. 10/573,227 · Granted Sep 1, 2009

Pyrimidine derivatives for treatment of hyperproliferative disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,582,645
App. No.
10/573,227
Granted
Sep 1, 2009
Kind
B2
Abstract

Pyrimidine derivatives of formula (I) in which J and Y represent aromatic or heteroaromatic rings; R 2 , G, G′, and G″ represent substituent groups and R 2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative diseases such as cancer are also disclosed and claimed.

Claims (406)

1. A compound having the structure

wherein

R 1 represents H, (C 1 -C 3 )alkyl, or cyclopropyl;

R 2 represents (C 1 -C 3 )alkyl, cyclopropyl, O(C 1 -C 3 )alkyl, or NR 3 R 4 wherein R 3 and R 4 are H, (C 1 -C 3 )alkyl, or cyclopropyl;

R 2a represents H or halogen;

M represents CH or N;

L represents a carbonyl group, O, NR 5 , CR 6 R 7 , or (C 2 -C 3 )alkylenyl which is optionally substituted up to twice by groups independently selected from halogen and OH;

wherein

R 5 is H or (C 1 -C 3 )alkyl; and

R 6 and R 7 are independently H, CH 3 , halogen, or OH;

J represents an aromatic or heteroaromatic ring selected from the group consisting of

Y represents an aromatic or heteroaromatic ring selected from the group consisting of

wherein R 8 represents H or (C 1 -C 3 )alkyl;

G″ represents a substituent selected from the group consisting of (C 1 -C 3 )alkyl, cyclopropyl, O(C 1 -C 3 )alkyl, halogen, CF 3 , CN and CO 2 R 9 ;

wherein

R 9 H or (C 1 -C 3 )alkyl; and

m represents the number of substituents G″, and is 0, 1, or 2;

G represents a substituent located on ring J;

G′ represents a substituent located on ring Y;

n represents the number of substituents G; and

n′ represents the number of substituents G′;

n and n′ are independently 0, 1, 2, or 3, subject to the provisos that

1) ring J and ring Y each may be substituted independently up to 3 times by substituents listed below as numbers G1-G2, to a maximum total of 4 substituents on rings J and Y,

2) ring J and ring Y each may be substituted independently up to 2 times by substituents listed below as numbers G3-G11, to a maximum total of 3 substituents on rings J and Y, and

3) ring J and ring Y each may be substituted independently once by a substituent selected from those listed below as numbers G12-G37;

and subject to the further provisos

4) when J is phenyl, G is other than OH or alkylthio; and when J is phenyl or pyridyl, n is 1, 2, or 3;

5) when J is phenyl, and G is G4 shown below, then R 2 is NR 3 R 4 ;

G and G′ moieties are independently selected from the group consisting of:

G1) halogen;

G2) O(C 1 -C 4 alkyl which optionally is substituted up to two times by O(C 1 -C 2 )alkyl;

G3) OH;

G4) (C 1 -C 5 )alkyl, which is optionally substituted independently up to two times by groups selected from hydroxyl and cyano, or up to three times by halogen;

G5) OCF 3 ;

G6) NHC(O)(C 1 -C 3 )alkyl;

G7) NHSO 2 (C 1 -C 3 )alkyl;

G8) NR 10 R 11 , wherein

 R 10 R 11 are independently selected from H, CH 3 , cyclopropyl, benzyl, NR 12 R 13 wherein

R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and

 (C 2 -C 4 )alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

 Q represents CH 2 , O, or NR 16 , and

 R 16 H or (C 1 -C 3 )alkyl, or

R 10 and R 11 may be joined to form a saturated 5-6-membered N-containing ring which is optionally substituted up to two times by OH, NR 17 R 18 , wherein R 17 and R 18 are H or (C 1 -C 3 )alkyl, or by (C 1 -C 3 )alkyl which is optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl;

G9) (CH 2 ) a -NR 19 R 20 wherein

R 19 and R 20 are independently H, (C 1 -C 5 )alkyl, or (C 3 -C 6 )cycloalkyl, or may be joined to form a saturated 5-6-membered N-containing ring; and

the subscript “a” is an integer of 1-4;

wherein

Q′ is O or NR 21 ;

R 21 is H, (C 1 -C 3 )alkyl, or cyclopropyl; and

the subscript “b” is an integer of 1-3;

G11) CH 2 NR 22 (CH 2 ) c OCH 3 wherein

R 22 is H, (C 1 -C 3 )alkyl, or cyclopropyl; and

the subscript “c” is an integer of 2-4;

G12) OSO 2 NR 23 R 24 wherein

R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 )alkyl which may optionally be substituted once by OH or NR 25 R 26 , wherein

 R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

G13) CN;

G14) NO 2 ;

G15) cyclopropyl;

G16) OR 27 , wherein

R 27 represents phenyl or benzyl;

G17) S(C 1 -C 3 )alkyl;

G18) CH═CH—(CH 2 ) 1-3 —OR 5 ; wherein

R 5 represents H or (C 1 -C 3 )alkyl;

G21) C(O)NR 28 R 29 , wherein R 28 and R 29 are independently selected from H, cyclopropyl, provided that both R 28 and R 29 are not simultaneously cyclopropyl,

 provided that this group does not constitute both R 28 and R 29 simultaneously, and

 (C 1 -C 3 )alkyl which is optionally substituted up to two times by OH; or

 R 28 and R 29 may be joined to form a saturated 5-6-membered N-containing ring which is optionally substituted up to two times by OH, or by (C 1 -C 3 )alkyl which in turn is optionally substituted up to two times by OH or O(C 1 -C 3 )alkyl;

 wherein

 Q″ is O or NR 30 , and

 R 30 is H, cyclopropyl, or (C 1 -C 3 )alkyl which is optionally substituted once by halogen, OH, or O(C 1 -C 3 )alkyl;

G23) O—(CH 2 ) d -NR 31 R 32 wherein R 31 and R 32 are independently H, (C 1 -C 3 )alkyl, or cyclopropyl, or may be joined to form a saturated 5-6-membered N-containing ring; and

 the subscript “d” is an integer of 2-4;

 wherein

the subscript “e” is an integer of 2-3; and

Q′″ is O or NR 33 ; and

R 33 is H, (C 1 -C 3 )alkyl, or cyclopropyl;

wherein

Q iv is O or NR 34 ; and

R 34 H, (C 1 -C 3 )alkyl, or cyclopropyl;

G26) C(O)NR 35 (CH 2 ) f OR 36 wherein

R 35 is H, (C 1 -C 3 )alkyl, or cyclopropyl;

R 36 is (C 1 -C 6 )alkyl optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl, and the subscript “f” is an integer of 2-4;

G27) CO 2 R 37 wherein

R 37 is H or (C 1 -C 3 )alkyl;

G28) phenyl, which is optionally substituted by up to 2 groups selected from halogen, (C 1 -C 3 )alkyl, OR 38 , CN, CF 3 , and NR 39 R 40 wherein

R 38 represents H or (C 1 -C 3 )alkyl; and

R 39 and R 40 represent H or (C 1 -C 3 )alkyl;

G29) NR 41 SO 2 NR 42 R 43 wherein

R 41 represents H, or (C 1 -C 4 )alkyl, and

R 42 and R 43 independently represent H, CH 3 , or (C 2 -C 3 )alkyl which may optionally be substituted once by —OH or NR 44 R 45 , wherein

 R 44 and R 45 independently represent H or (C 1 -C 3 )alkyl;

G30) OC(O)—CH 2 —NR 46 R 47 wherein

R 46 and R 47 independently represent H, (C 1 -C 3 )alkyl, or CO 2 (t-butyl), provided that R 46 and R 47 are not both simultaneously CO 2 (t-butyl);

G31) N(R 48 )C(O)R 49 wherein

R 48 represents H or (C 1 -C 3 )alkyl; and

R 49 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 alkyl, (CH 2 ) 1-4 —NR 50 R 51 wherein

 R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or CH(R 52 )—NR 53 R 54 wherein

 R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

 R 53 and R 54 independently represent H or (C 1 -C 3 )alkyl;

G32) C(O)—(C 1 -C 3 )alkyl;

G33) (CH 2 ) g -N(R 55 )—C(O)R 56 wherein

g represents 1, 2, or 3;

R 55 represents H or (C 1 -C 3 )alkyl;

R 56 represents

 (C 1 -C 3 )alkyl optionally substituted up to two times by OR 57 or NR 58 R 59 , wherein

 R 57 represents H or (C 1 -C 3 )alkyl, and

 R 58 and R 59 each represents H or (C 1 -C 3 )alkyl, or represents wherein

 wherein

 R 60 represents halogen, (C 1 -C 3 )alkyl, O(C 1 -C 3 )alkyl, CN, OH, CF 3 , or NR 61 R 62 , wherein

 R 61 and R 62 represent H or (C 1 -C 3 )alkyl; and

 h represents 0, 1, or 2;

G34) (CH 2 ) i —N(R 63 )—C(O)—NR 64 R 65 wherein

i represents 1, 2, or 3;

R 63 represents H or (C 1 -C 3 )alkyl;

R 64 and R 65 each represents H or (C 1 -C 3 )alkyl; or

R 64 and R 65 may be joined to form

 wherein Q V represents CH 2 , O or NR 66 wherein R 66 represents H or (C 1 -C 3 )alkyl;

 wherein

 j represents 1, 2, or 3;

 R 67 represents H or (C 1 -C 3 )alkyl; and

 R 68 represents H or (C 1 -C 3 )alkyl;

G36) (CH 2 ) k —N(R 69 )—SO 2 —R 70 wherein

k represents 1, 2, or 3;

R 69 represents H or (C 1 -C 3 )alkyl; and

R 70 represents (C 1 -C 4 alkyl, or phenyl which is optionally substituted up to perhalo by halogen or up to three times by OR 71 , CN, CF 3 , or NR 72 R 73 , wherein

 R 71 represents H or (C 1 -C 3 )alkyl; and

 R 72 and R 73 each represents H or (C 1 -C 3 )alkyl;

G37) CH═CH—(CH 2 ) 1-3 —NR 74 R 75 wherein R 74 and R 75 represent H or (C 1 -C 3 )alkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound of claim 1 wherein R 1 H;

M represents CH;

J represents a heteroaromatic ring selected from the group consisting of

Y represents an aromatic or heteroaromatic ring selected from the group consisting of

n and n′ are independently 0, 1, 2, or 3, subject to the provisos that

1) ring J and ring Y each may be substituted independently up to 3 times by substituents listed below as numbers G1-G2, to a maximum total of 4 substituents on rings J and Y,

2) ring J and ring Y each may be substituted independently up to 2 times by substituents listed below as numbers G3-G5 and G8, to a maximum total of 3 substituents on rings J and Y, and

3) ring J and ring Y each may be substituted independently once by a substituent selected from those listed below as numbers G12, G13, G22, G29, and G31;

and subject to the further proviso

4) when J is pyridyl, n is 1, 2, or 3;

and proviso 5 does not apply;

G and G′ moieties are independently selected from the group consisting of:

G1) halogen;

G2) O(C 1 -C 4 )alkyl which optionally is substituted up to two times by O(C 1 -C 2 )alkyl;

G3) OH;

G4) (C 1 -C 5 )alkyl, which is optionally substituted independently up to two times by groups selected from hydroxyl and cyano, or up to three times by halogen;

G5) OCF 3 ;

G8) NR 10 R 11 , wherein

 R 10 R 11 are independently selected from H, CH 3 , cyclopropyl, benzyl, NR 12 R 13 wherein

R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and (C 2 -C 4 alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

Q represents CH 2 , O, or NR 16 , and

R 16 H or (C 1 -C 3 )alkyl, or

 R 10 and R 11 may be joined to form a saturated 5-6-membered N-containing ring which is optionally substituted up to two times by OH, NR 17 R 18 , wherein R 17 and R 18 are H or (C 1 -C 3 )alkyl, or by (C 1 -C 3 )alkyl which is optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl;

G12) OSO 2 NR 23 R 24 wherein

R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 alkyl which may optionally be substituted once by OH or NR 26 R 27 , wherein

R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

G13) CN;

 wherein

 Q″ is O or NR 30 , and

 R 30 is

H, cyclopropyl, or (C 1 -C 3 )alkyl which is optionally substituted once by halogen, OH, or O(C 1 -C 3 )alkyl;

G29) NR 41 SO 2 NR 42 R 43 wherein

R 41 represents H, or (C 1 -C 4 )alkyl, and

R 42 and R 43 independently represent H, CH 3 , or (C 2 -C 3 )alkyl which may optionally be substituted once by —OH or NR 44 R 45 , wherein

R 44 R 45 independently represent H or (C 1 -C 3 )alkyl; and

G31) N(R 48 )C(O)R 49 wherein

R 48 represents H or (C 1 -C 3 )alkyl; and

R 49 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 )alkyl, (CH 2 ) 1-4 —NR 50 R 51 wherein

R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or

CH(R 52 )—NR 53 R 54 wherein

R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

R 53 R 54 independently represent H or (C 1 -C 3 )alkyl.

3. The compound of claim 2 wherein

R 1 H;

R 2 represents O(C 1 -C 3 )alkyl or NR 3 R 4 wherein R 3 and R 4 are H or (C 1 -C 3 )alkyl;

R 2a represents H;

L represents O or CR 6 R 7 wherein

R 6 R 7 independently H, CH 3 , or OH;

G″ represents a substituent selected from the group consisting of O(C 1 -C 3 )alkyl, halogen, and CF 3 ;

n and n′ are independently 0 or 1, and provisos 1-3 do not apply;

G and G′ moieties are independently selected from the group consisting of:

G1) Cl or F;

G2) O(C 1 -C 3 )alkyl;

G3) OH;

G4) (C 1 -C 3 )alkyl, which is optionally substituted up to three times by halogen;

G5) OCF 3 ;

G8) NR 10 R 11 , wherein

 R 10 R 11 are independently selected from

H, CH 3 , cyclopropyl, benzyl,

NR 12 R 13 wherein

 R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and

(C 2 -C 4 alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

Q represents CH 2 , O, or NR 16 , and

R 16 represents H or (C 1 -C 3 )alkyl,

G12) OSO 2 NR 23 R 24 wherein

 R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 )alkyl which may optionally be substituted once by OH or NR 25 R 26 , wherein

 R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

G13) CN;

 wherein

Q″ is O or NR 30 , and

R 30 is H or (C 1 -C 3 )alkyl; and

G31) N(R 48 )C(O)R 49 wherein

 R 48 represents H or (C 1 -C 3 )alkyl; and

 R 9 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 alkyl,

(CH 2 ) 1-4 —NR 50 R 51 wherein

R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or CH(R 52 )—NR 53 R 54 wherein

R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

R 53 and R 54 independently represent H or (C 1 -C 3 )alkyl.

4. The compound of claim 1 wherein

R 1 represents H;

M represents CH;

J represents a heteroaromatic ring selected from the group consisting of

Y represents an aromatic or heteroaromatic ring selected from the group consisting of

n and n′ are independently 0, 1, 2, or 3, subject to the provisos that

1) ring J and ring Y each may be substituted independently up to 3 times by substituents listed below as numbers G1-G2, to a maximum total of 4 substituents on rings J and Y,

2) ring J and ring Y each may be substituted independently up to 2 times by substituents listed below as numbers G3-G5 and G8, to a maximum total of 3 substituents on rings J and Y, and

3) ring J and ring Y each may be substituted independently once by a substituent selected from those listed below as numbers G12, G21, G25, G26, and G31;

and subject to the further proviso

4) when J is pyridyl, n is 1, 2, or 3;

and proviso 5 does not apply;

G and G′ moieties are independently selected from the group consisting of:

G1) halogen;

G2) O(C 1 -C 4 alkyl which optionally is substituted up to two times by O(C 1 -C 2 )alkyl;

G3) OH;

G4) (C 1 -C 5 )alkyl, which is optionally substituted independently up to two times by groups selected from hydroxyl and cyano, or up to three times by halogen;

G5) OCF 3 ;

G8) NR 10 R 11 , wherein

 R 10 and R 11 are independently selected from H, CH 3 , cyclopropyl, benzyl,

NR 12 R 13 wherein

R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and

(C 2 -C 4 alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

Q represents CH 2 , O, or NR 16 , and

R 16 H or (C 1 -C 3 )alkyl, or

 R 10 and R 11 may be joined to form a saturated 5-6-membered N-containing ring which is optionally substituted up to two times by OH, NR 17 R 18 , wherein R 17 and R 18 are H or (C 1 -C 3 )alkyl, or by

(C 1 -C 3 )alkyl which is optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl;

G12) OSO 2 NR 23 R 24 wherein

 R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 )alkyl which may optionally be substituted once by OH or NR 25 R 26 , wherein

 R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

G21) C(O)NR 28 R 29 , wherein

R 28 and R 29 are independently selected from H, cyclopropyl, provided that both R 28 and R 29 are not simultaneously cyclopropyl,

 provided that this group does not constitute both R 28 and R 29 simultaneously, and (C 1 -C 3 )alkyl which is optionally substituted up to two times by OH; or

 R 28 and R 29 may be joined to form a saturated 5-6-membered N-containing ring which is optionally substituted up to two times by OH, or by (C 1 -C 3 )alkyl which in turn is optionally substituted up to two times by OH or O(C 1 -C 3 )alkyl;

wherein

 Q iv is O or NR 34 ; and

 R 34 is H, (C 1 -C 3 )alkyl, or cyclopropyl;

G26) C(O)NR 35 (CH 2 ) f OR 36 wherein

R 35 is H, (C 1 -C 3 )alkyl, or cyclopropyl;

R 36 is (C 1 -C 6 )alkyl optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl, and the subscript “f” is an integer of 2-4; and

G31) N(R 48 )C(O)R 49 wherein

 R 48 represents H or (C 1 -C 3 )alkyl; and

 R 49 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 )alkyl,

(CH 2 ) 1-4 —NR 50 R 51 wherein

R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or CH(R 52 )—NR 53 R 54 wherein

R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

R 53 and R 54 independently represent H or (C 1 -C 3 )alkyl.

5. The compound of claim 4 wherein

R 1 represents H;

R 2 represents O(C 1 -C 3 )alkyl or NR 3 R 4 wherein R 3 and R 4 are H or (C 1 -C 3 )alkyl;

R 2a represents H;

L represents O or CR 6 R 7 , wherein

R 6 R 7 are independently H, CH 3 , or OH;

G 41 represents a substituent selected from the group consisting of O(C 1 -C 3 )alkyl, halogen, and CF 3 ;

n and n′ are independently 0 or 1, and provisos 1-3 do not apply;

G and G′ moieties are independently selected from the group consisting of:

G1) Cl or F;

G2) O(C 1 -C 3 )alkyl;

G3) OH;

G4) (C 1 -C 3 )alkyl, which is optionally substituted up to three times by halogen;

G5) OCF 3 ;

G8) NR 10 R 11 , wherein

R 10 and R 11 are independently selected from H, CH 3 , cyclopropyl, benzyl, NR 12 R 13 wherein

R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and

(C 2 -C 4 alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

Q represents CH 2 , O, or NR 16 , and

R 16 represents H or (C 1 -C 3 )alkyl,

G12) OSO 2 NR 23 R 24 wherein

R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 alkyl which may optionally be substituted once by OH or NR 25 R 26 , wherein

R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

G21) C(O)NR 28 R 29 , wherein

R 28 and R 29 are independently selected from H and (C 1 -C 3 )alkyl which is optionally substituted up to two times by OH;

wherein

Q iv is O or NR 34 ; and

R 34 H or (C 1 -C 3 )alkyl;

G26) C(O)NR 35 (CH 2 ) f OR 36 wherein

R 35 is H or (C 1 -C 3 )alkyl;

R 36 is (C 1 -C 6 )alkyl optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl, and the subscript “f” is an integer of 2-4; and

G31) N(R 48 )C(O)R 49 wherein

R 48 represents H or (C 1 -C 3 )alkyl; and

R 49 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 alkyl,

(CH 2 ) 1-4 —NR 50 R 51 wherein

R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or

CH(R 52 )—NR 53 R 54 wherein

R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

R 53 and R 54 independently represent H or (C 1 -C 3 )alkyl.

6. The compound of claim 1 wherein

R 1 represents H;

M represents CH;

J represents an aromatic or heteroaromatic ring selected from the group consisting of

Y represents an aromatic or heteroaromatic ring selected from the group consisting of

n and n′ are independently 0, 1, 2, or 3, subject to the provisos that

1) ring J and ring Y each may be substituted independently up to 3 times by substituents listed below as numbers G1-G2, to a maximum total of 4 substituents on rings J and Y,

2) ring J and ring Y each may be substituted independently up to 2 times by substituents listed below as numbers G3-G5 and G8, to a maximum total of 3 substituents on rings J and Y, and

3) ring J and ring Y each may be substituted independently once by a substituent selected from those listed below as numbers G12, G22, and G31;

and subject to the further proviso

4) when J is pyridyl, n is 1, 2, or 3;

and proviso 5 does not apply;

G and G′ moieties are independently selected from the group consisting of:

G1) halogen;

G2) O(C 1 -C 4 alkyl which optionally is substituted up to two times by O(C 1 -C 2 )alkyl;

G3) OH;

G4) (C 1 -C 5 )alkyl, which is optionally substituted independently up to two times by groups selected from hydroxyl and cyano, or up to three times by halogen;

G5) OCF 3 ;

G8) NR 10 R 11 , wherein

R 10 R 11 are independently selected from H, CH 3 , cyclopropyl, benzyl, NR 12 R 13 wherein

R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and

 (C 2 -C 4 alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

Q represents CH 2 , O, or NR 16 , and

R 16 represents H or (C 1 -C 3 )alkyl, or

R 10 and R 11 may be joined to form a saturated 5-6-membered N-containing ring which is optionally substituted up to two times by OH, NR 17 R 18 , wherein

 R 17 and R 18 are H or (C 1 -C 3 )alkyl, or by

 (C 1 -C 3 )alkyl which is optionally substituted up to two times by halogen, OH, or O(C 1 -C 3 )alkyl;

G12) OSO 2 NR 23 R 24 wherein

R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 alkyl which may optionally be substituted once by OH or NR 25 R 26 , wherein

R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

wherein

 Q″ is O or NR 30 , and

 R 30 is H, cyclopropyl, or (C 1 -C 3 )alkyl which is optionally substituted once by halogen, OH, or O(C 1 -C 3 )alkyl; and

G31) N(R 48 )C(O)R 49 wherein

R 48 represents H or (C 1 -C 3 )alkyl; and

R 49 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 )alkyl,

(CH 2 ) 1-4 —NR 50 R 51 wherein

 R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or

CH(R 52 )—NR 53 R 54 wherein

 R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

 R 53 and R 54 independently represent H or (C 1 -C 3 )alkyl.

7. The compound of claim 6 wherein

R 1 represents H;

R 1 represents O(C 1 -C 3 )alkyl, or NR 3 R 4 wherein R 3 and R 4 are H or (C 1 -C 3 )alkyl;

R 2a represents H;

L represents O or CR 6 R 7 , wherein

R 6 and R 7 are independently H, CH 3 , or OH;

G″ represents a substituent selected from the group consisting of O(C 1 -C 3 )alkyl, halogen, and CF 3 ;

n and n′ are independently 0 or 1, and provisos 1-3 do not apply;

G and G′ moieties are independently selected from the group consisting of:

G1) Cl or F;

G2) O(C 1 -C 3 )alkyl;

G3) OH;

G4) (C 1 -C 3 )alkyl, which is optionally substituted up to three times by halogen;

G5) OCF 3 ;

G8) NR 10 R 11 , wherein

R 10 and R 11 are independently selected from H, CH 3 , cyclopropyl, benzyl, NR 12 R 13 wherein

R 12 and R 13 are independently H or (C 1 -C 3 )alkyl, provided that both R 10 and R 11 are not NR 12 R 13 simultaneously, and

(C 2 -C 4 )alkyl which is optionally substituted up to three times by halogen, and up to two times by substituent groups independently selected from hydroxyl, O(C 1 -C 3 )alkyl, and NR 14 R 15 , wherein

R 14 and R 15 are independently H or (C 1 -C 3 )alkyl, or

R 14 and R 15 can join to form a heterocycle of formula

wherein

Q represents CH 2 , O, or NR 16 , and

R 16 represents H or (C 1 -C 3 )alkyl;

G12) OSO 2 R 23 R 24 wherein

R 23 and R 24 independently represent H, CH 3 , or (C 2 -C 4 )alkyl which may optionally be substituted once by OH or NR 25 R 26 wherein

R 25 and R 26 independently represent H or (C 1 -C 3 )alkyl;

wherein

Q″ is O or NR 30 , and

R 30 is H or (C 1 -C 3 )alkyl; and

G31) N(R 48 )C(O)R 49 wherein

R 48 represents H or (C 1 -C 3 )alkyl; and

R 49 represents (CH 2 ) 1-3 —CO 2 H, O(C 2 -C 4 )alkyl,

(CH 2 ) 1-4 —NR 50 R 51 wherein

R 50 and R 51 independently represent H or (C 1 -C 3 )alkyl, or

(CH(R 52 )—NR 53 R 54 wherein

 R 52 represents (CH 2 ) 1-4 —NH 2 , CH 2 OH, CH(CH 3 )OH, or (C 1 -C 3 )alkyl; and

 R 53 and R 54 independently represent H or (C 1 -C 3 )alkyl.

8. A compound selected from the group consisting of

4-{3-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;

4-{3-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy}pyridine-2-carboxamide;

4-{4-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy}pyridine-2-carbonitrile;

6-phenyl-N 4 -(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine;

N 4 -{4-[(2-chloropyridin-4-yl)oxy]phenyl}-6-phenylpyrimidine-2,4-diamine;

4-{2-amino-6-[(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)amino]pyrimidin-4-yl}phenyl sulfamate;

N-(4-{2-amino-6-[(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)amino]pyrimidin-4-yl}phenyl)glycinamide trifluoroacetate;

6-(4-aminophenyl)-N 4 -(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine;

6-(6-aminopyridin-3-yl)-N 4 -(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine;

6-pyridin-3-yl-N 4 -(4-{[2-(trifluoromethyl)pyridin-4-yl]oxy}phenyl)pyrimidine-2,4-diamine;

N-[(4-{4-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy}pyridin-2-yl)methyl]-4-methoxybenzenesulfonamide trifluoroacetate;

N-[(4-{4-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy}pyridin-2-yl)methyl]methanesulfonamide trifluoroacetate; and

(4-{4-[(2-amino-6-phenylpyrimidin-4-yl)amino]phenoxy}pyridin-2-yl)methanol trifluoroacetate (salt).

9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

10. A method of treatment of breast cancer comprising administering an effective amount of a compound of claim 1 to a subject in need thereof.